Jove
Visualize
Contact Us

Related Experiment Videos

BiDil: from another vantage point.

Gary Puckrein1

  • 1National Minority Health Month Foundation in Washington, DC, USA. gpuckrein@americanvisions.com

Health Affairs (Project Hope)
|August 17, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regional and racial outcomes in mortality after atrial fibrillation ablation in medicare Fee for service patients.

Frontiers in cardiovascular medicine·2026
Same author

Vitamin D Levels and SARS-CoV-2 Infection among Medically Underserved Populations in the Minority and Rural Coronavirus Insights Study.

Viruses·2024
Same author

Nucleocapsid and Spike Protein-Based Anti-SARS-CoV-2 Assay Performance in the Minority and Rural Coronavirus Insights Study: Characteristics of Socioeconomically Disadvantaged Populations with Health Disparities.

The journal of applied laboratory medicine·2024
Same author

The Minority and Rural Coronavirus Insights Study: Design and Baseline Characteristics of a Minority Cohort.

Population health management·2023
Same author

Geographic Variation in Racial Disparities in Receipt of High-Dose Influenza Vaccine Among US Older Adults.

Journal of racial and ethnic health disparities·2023
Same author

Demographic Determinants and Geographical Variability of COVID-19 Vaccine Hesitancy in Underserved Communities: Cross-sectional Study.

JMIR public health and surveillance·2023
Same journal

National Health Expenditure Projections, 2025-34: Strong Utilization Growth Initially, Legislative Impacts Later.

Health affairs (Project Hope)·2026
Same journal

State Medicaid Programs Face Increased Spending On Medicare Premiums.

Health affairs (Project Hope)·2026
Same journal

Not enough time.

Health affairs (Project Hope)·2026
Same journal

Medicaid Tobacco And Nicotine Cessation Treatment Rates Remained Low, 2019-24.

Health affairs (Project Hope)·2026
Same journal

Third-Party Convener Firms And The Rise Of Geographically Dispersed, High-Earning Medicare ACOs.

Health affairs (Project Hope)·2026
Same journal

The Opacity Of Price Transparency.

Health affairs (Project Hope)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

This study confirms persistent disparities in heart failure among African Americans, validating the effectiveness of BiDil. Denying this life-saving drug based on flawed arguments would harm patients.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacogenomics
  • Health Disparities Research

Background:

  • The drug BiDil, approved by the Food and Drug Administration (FDA) for treating heart failure in African Americans, has faced criticism.
  • Concerns have been raised regarding the existence of racial disparities in heart failure and the motivations behind BiDil's development and marketing.

Purpose of the Study:

  • To critically evaluate the arguments against the FDA's approval of BiDil for heart failure treatment in African Americans.
  • To examine the evidence supporting racial disparities in heart failure prevalence and outcomes.
  • To assess the proven efficacy of BiDil in the target population.

Main Methods:

  • Review and analysis of existing scientific literature and clinical trial data on heart failure disparities.

Related Experiment Videos

  • Examination of the pharmacological basis and clinical effectiveness studies for BiDil.
  • Critical appraisal of arguments questioning the scientific and ethical basis for BiDil's targeted approval.

    • Main Results:

    • Confirmed and persistent disparities in heart failure exist among African American patients compared to other populations.
    • Clinical evidence demonstrates the effectiveness of BiDil in treating heart failure within this demographic.
    • Arguments against BiDil's approval are based on a flawed questioning of established disparities and proven drug efficacy.

    Conclusions:

    • The continued approval and use of BiDil are crucial for providing life-saving therapy to African American heart failure patients.
    • Challenging BiDil's efficacy based on the presented arguments would unjustly deny patients access to a beneficial treatment.
    • Further research should focus on refining patient identification to maximize the benefits of BiDil therapy.